Janssen, Mylan settle patent fight on contraceptive

By Eric Palmer Janssen Pharmaceuticals has again temporarily wrestled to the ground another potential generics competitor to its Ortho Tri-Cyclen Lo contraceptive. Mylan ($MYL) said ...

Novo Nordisk’s Tresiba gets panel backing, but with caveats

By Eric Palmer An FDA advisory panel’s recommendation for the approval of Novo Nordisk’s long-lasting insulin Tresiba, with provisos, was mixed news for both Novo and ...

Italy lifts ban on Novartis vaccines

By Eric Palmer The leader of the pack has come around on Novartis’ ($NVS) flu vaccines. The company said authorities in Italy have lifted a ban on a number of Novartis vaccines ...

CVS shucking more drugs from its coverage list

AndroGel, Lumigan, Onglyza added to CVS no-coverage list By Eric Palmer Beginning in January, the list of drugs CVS Caremark’s ($CVS) pharmacy-benefit business will refuse to ...

NICE reverses position on Novartis’ Xolair

By Eric Palmer NICE, the drug price watchdog in the U.K., says it has changed its mind on Xolair, the severe asthma drug from Novartis ($NVS). It announced today that it no longer ...

Sanofi halves the cost of controversial new cancer drug Zaltrap

By Eric Palmer and Tracy Staton Sanofi ($SNY) has put Zaltrap on sale for 50% off. The colorectal cancer drug isn’t an overstock, but a brand-new product, approved by FDA ...

Stem cell developer reveals second patient death as criticism builds

By Ryan McBride Pluristem Therapeutics ($PSTI) fired off a press release yesterday demanding corrections to a Bloomberg article this week about the company’s stock sale that ...

GSK reports letdown in PhIII malaria vaccine study

By Ryan McBride In a study inspired by hope of routing malaria in African babies, GlaxoSmithKline’s ($GSK) experimental vaccine failed to live up to expectations. The experimental ...

Takeda takes aim at becoming next big vaccine developer

By Ryan McBride Takeda is wheeling and dealing in an effort to become a global player in the vaccines business, a fast-growing market dominated by the likes of GlaxoSmithKline ($GSK), ...

Cardioxyl Pharma reports $28M equity round with lead drug against heart failure

By Ryan McBride With a lead candidate in development for a big cardio market, Cardioxyl Pharmaceuticals has wrapped up a $28.1 million round of equity financing, according to an SEC ...

Gates Foundation backs $13M venture add for flu drug developer

By John Carroll The Bill & Melinda Gates Foundation has stepped up with another equity investment in a biotech company, this time making a major contribution to a $13 million ...

UPDATED: FDA advisers endorse Novo Nordisk’s key diabetes drug

By Ryan McBride Novo Nordisk ($NVO) declared victory after an FDA advisory committee meeting on the company’s long-lasting insulin product degludec or Tresiba, a blockbuster ...
Page 1 of 9312345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS